BioTelemetry's (BEAT) MCOT Patch Approved by U.S. FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 2/4/2023
- Wall Street ends down after stunning jobs growth raises Fed questions
- Elon Musk wins 'funding secured' trial
- U.S. nonfarm payroll growth blows past forecasts in January, up 517k
- Analysts defend Apple (AAPL) as earnings miss drags shares lower
- Amazon (AMZN) drops after earnings, analysts worried about AWS uncertainty
- Ford Motor (F) Declares $0.65 Special Dividend; 4.5% Yield
- Heart Test Laboratories (HSCS) Announces Further Internationalization of its Patent Portfolio
- Wall Street ends down after stunning jobs growth raises Fed questions
- Ford Motor (F) Declares $0.15 Quarterly Dividend; 4.2% Yield
- Walt Disney (DIS) could sell more films and TV series to rivals - Bloomberg
- Apple, Amazon, Alphabet, Ford all fall in premarket
- After-hours movers: Apple, Amazon, and Google all fall as results disappoint
- Meta leaps in premarket, pulling Amazon, Alphabet higher; Estee Lauder falls
- After-hours movers: Meta surges on better results, lifts other FAANG stocks
- Midday movers: Peloton Interactive, Electronic Arts, Match Group and more
BioTelemetry, Inc. Announces FDA Approval of Its Next Generation Device, the MCOT™ Patch
July 26, 2016 8:30 AM EDTMALVERN, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ: BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of its next generation Mobile Cardiac Outpatient Telemetry device, the MCOT Patch. The MCOT Patch is a four-lead, two-channel system which provides the same best in class technology as the current MCOT, in a more convenient form factor. The MCOT devices, through the use of a... More
